The patent infringement lawsuit highlights the competitive landscape in the pharmaceutical industry, especially within the gastrointestinal health sector. For Bausch Health, XIFAXAN® is not just a product but a major revenue driver. The fight to keep generics off the market underscores how valuable this drug is to the company's portfolio. Historically, once a blockbuster drug like XIFAXAN® faces generic competition, the branded version's sales can decline by over 80% within the first year of generic entry due to the significant price drop generics introduce.